Vivani Medical, Inc.
VANIVivani Medical, Inc. in brief
Vivani Medical, Inc. is a listed company in the Medical Devices industry, based in Alameda, California, USA. Its market value was $121 M on 1 August 2026, which makes it the 18,053rd largest listed company in the world and the 3,420th largest in the USA on this site. It employs about 36 people and Adam Mendelsohn is its chief executive. Its shares trade under the symbol VANI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Vivani Medical, Inc.
Vivani Medical, Inc. is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal™ technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address leading causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients.
From the company's annual report filed with the US SEC: read the report
Vivani Medical, Inc. timeline
- 2003
- ✎Renamed Second Sight Medical Products IncFormerly Secound Sight Medical Products Inc.
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- 🔔· approximateInitial public offering on Nasdaq
- 2022
- ✎Renamed Vivani Medical, Inc.Formerly Second Sight Medical Products Inc.
- 2025
- 💰Record net income of $27 millionFY2025, the highest profit of the 3 years on record.
Events of Vivani Medical, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,836 (Dec 2022) · #4,575 (Jul 2023) · #4,016 (Jan 2024) · #1,957 (Mar 2026) · #3,336 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 7.7×
- Free cash flow yield
- -21.1%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -169.2%
- Liabilities / assets
- 60.1%
- Revenue growth
- -51.0%
- R&D / revenue
- 388.8%
- Profit per employee
- $-739 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-28M | $-27M | — |
| Dec 2024 | — | — | $-25M | $-23M | — |
| Dec 2023 | — | — | $-27M | $-26M | — |
| Dec 2022 | — | — | $-21M | $-14M | — |
| Dec 2020 | — | — | $-15M | $-15M | — |
| Dec 2019 | $3M | -51.0% | $-34M | $-34M | -993.8% |
| Dec 2018 | $7M | -13.3% | $-35M | $-35M | -508.6% |
| Dec 2017 | $8M | — | $-29M | $-29M | -358.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-24M | $1M | $-25M | $-0.43 | — |
| Dec 2024 | $-21M | $1M | $-21M | $-0.43 | — |
| Dec 2023 | $-24M | $1M | $-25M | $-0.50 | — |
| Dec 2022 | $-19M | $0M | $-19M | — | — |
| Dec 2020 | $-17M | $0M | $-17M | $-0.72 | — |
| Dec 2019 | $-28M | $0M | $-28M | $-2.28 | — |
| Dec 2018 | $-30M | $0M | $-30M | $-4.23 | — |
| Dec 2017 | $-24M | $0M | $-24M | $-0.53 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure · Other events
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 30, 20268-KCurrent reportRegulation FD disclosure
- Oct 29, 20268-KCurrent reportRegulation FD disclosure
- Sep 16, 20268-KCurrent reportRegulation FD disclosure
- Aug 17, 20268-KCurrent reportRegulation FD disclosure
- Aug 13, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportRegulation FD disclosure
- Jul 16, 20268-KCurrent reportRegulation FD disclosure
- Jul 7, 20268-KCurrent reportMaterial agreement · Other events
- Jun 30, 20268-KCurrent reportDirectors or officers changed · Shareholder vote · Other events
Official filings of Vivani Medical, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-28 M
- Net income
- $-27 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $39 M
- Total liabilities
- $24 M
- Total equity
- $16 M
As of December-2025
Top 38 institutional investors in Vivani Medical, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 1,437,373 | -330,704 (-18.70%) | 1.59% | $2 M | Nov 13, 2026 |
| 2 | Tanager Wealth Management LLP | 607,276 | 0 (0.00%) | 0.67% | $1 M | Oct 19, 2026 |
| 3 | Geode Capital Management, LLC | 518,622 | -69,123 (-11.76%) | 0.57% | $1 M | Nov 6, 2026 |
| 4 | Commonwealth Equity Services, LLC | 320,565 | -10,000 (-3.03%) | 0.36% | $0 M | Nov 2, 2026 |
| 5 | BlackRock, Inc. | 293,187 | -8,641 (-2.86%) | 0.33% | $0 M | Nov 13, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 232,318 | -93,144 (-28.62%) | 0.26% | $0 M | Nov 13, 2026 |
| 7 | Monetary Management Group Inc | 193,977 | 0 (0.00%) | 0.21% | $0 M | Nov 16, 2026 |
| 8 | Susquehanna International Group, LLP | 155,779 | +127,433 (+449.56%) | 0.17% | $0 M | Nov 16, 2026 |
| 9 | State Street Corp | 154,965 | 0 (0.00%) | 0.17% | $0 M | Nov 12, 2026 |
| 10 | Jane Street Group, LLC | 122,343 | New | 0.14% | $0 M | Nov 12, 2026 |
| 11 | Northern Trust Corp | 116,907 | 0 (0.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 12 | Arax Advisory Partners | 100,000 | New | 0.11% | $0 M | Nov 12, 2026 |
| 13 | MAI Capital Management | 99,870 | 0 (0.00%) | 0.11% | $0 M | Nov 12, 2026 |
| 14 | Millennium Management LLC | 70,730 | New | 0.08% | $0 M | Nov 16, 2026 |
| 15 | Citadel Advisors LLC | 54,758 | New | 0.06% | $0 M | Nov 16, 2026 |
| 16 | Gsa Capital Partners LLP | 54,146 | -6,720 (-11.04%) | 0.06% | $0 M | Nov 16, 2026 |
| 17 | Armstrong Advisory Group, Inc | 25,000 | -20,000 (-44.44%) | 0.03% | $0 M | Oct 9, 2026 |
| 18 | Schonfeld Strategic Advisors LLC | 19,000 | New | 0.02% | $0 M | Nov 16, 2026 |
| 19 | Vanguard Global Advisers, LLC | 16,279 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 20 | Focus Partners Wealth | 16,144 | New | 0.02% | $0 M | Nov 12, 2026 |
| 21 | StoneX Group Inc. | 15,369 | +1,226 (+8.67%) | 0.02% | $0 M | Nov 3, 2026 |
| 22 | Marshall Wace, LLP | 11,161 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 23 | Lazari Capital Management, Inc. | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 20, 2026 |
| 24 | Simplex Trading, LLC | 3,787 | New | 0.00% | $0 M | Nov 4, 2026 |
| 25 | Steward Partners Investment Advisory, LLC | 2,000 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Show all 38: investors 26 to 38
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Jpmorgan Chase & Co | 1,662 | -1,727 (-50.96%) | 0.00% | $0 M | Nov 12, 2026 |
| 27 | Jones Financial Companies Lllp | 1,200 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 28 | SBI Securities Co., Ltd. | 1,165 | +1 (+0.09%) | 0.00% | $0 M | Oct 22, 2026 |
| 29 | Rothschild Investment LLC | 1,000 | New | 0.00% | $0 M | Nov 10, 2026 |
| 30 | Pinnacle Financial Group, Inc. | 796 | — | 0.00% | $0 M | Nov 16, 2026 |
| 31 | Osaic Holdings, Inc. | 220 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 32 | UBS Group AG | 202 | -50,906 (-99.60%) | 0.00% | $0 M | Nov 10, 2026 |
| 33 | NFSG Corp | 103 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 34 | Highland Investment Advisors LLC | 32 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 35 | Caitong International Asset Management Co., Ltd | 13 | +7 (+116.67%) | 0.00% | $0 M | Oct 29, 2026 |
| 36 | Barclays PLC | 11 | -652 (-98.34%) | 0.00% | $0 M | Nov 6, 2026 |
| 37 | Danske Bank A/s | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 38 | Morgan Stanley | 1 | -9 (-90.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Vivani Medical, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.11 M | $1 M | 1.2% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 643,786 | $1 M | 0.71% | <0.01% | −0.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 283,769 | $0 M | 0.31% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 133,707 | $0 M | 0.15% | 0.01% | +2.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 69,679 | $0 M | 0.08% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 58,567 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 47,626 | $0 M | 0.05% | <0.01% | +27% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 13,244 | $0 M | 0.01% | <0.01% | −63% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 8,403 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 4,637 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Vivani Medical, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gregg WilliamsDirector, 10% owner | Buyindirect | +29,929 | $1.051 | $31 K | 36.99 M | Form 4 |
| filed | Gregg WilliamsDirector, 10% owner | Buyindirect | +2,100 | $1.010 | $2 K | 36.96 M | Form 4 |
| filed | Gregg WilliamsDirector, 10% owner | Buyindirect | +48,100 | $0.993 | $48 K | 36.96 M | Form 4 |
| filed | Donald DwyerChief Business Officer | Buy | +5,000 | $0.830 | $4 K | 60,000 | Form 4 |
| filed | Donald DwyerChief Business Officer | Buy | +15,000 | $1.033 | $15 K | 75,000 | Form 4 |
| filed | Aaron MendelsohnDirector | Gift | -20,000 | — | — | 168,170 | Form 4 |
| filed | Gregg WilliamsDirector, 10% owner | Buyindirect | +793,650 | $1.260 | $1000 K | 36.91 M | Form 4 |
| filed | Gregg WilliamsDirector, 10% owner | Buyindirect | +1.59 M | $1.260 | $2.0 M | 36.12 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Vivani Medical, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 8-for-1 split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2015 | Q1 2015 | $0.1M |
Fails to deliver
- : 73,147 shares at $1.38
- : 73,147 shares at $1.38
- : 73,147 shares at $1.41
- : 74,250 shares at $1.39
- : 238,815 shares at $1.35
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Vivani Medical, Inc. scorecard#
Passes 1 of the 7 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.43 vs -0.43Diluted EPS -0.43 in fiscal 2025 against -0.43 the year before (report's currency).
- ✗Net income higher than five years earlier-$27 M-$27 M in fiscal 2025 against -$15 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$27 MNet income -$27 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-159.6%-159.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.7×Current ratio 2.71 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year13.5%Diluted shares up 13.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Vivani Medical, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0—— | 0—— | — | — | — | — | 3.4−51.0%100% | 6.9−13.4%100% | 8.0+99.1%100% | 4.0—100% | |
| Cost of revenue | — | — | — | — | 0.1−74.0%— | 0.5−76.8%— | 2.2−56.0%63.7% | 4.9−4.5%70.9% | 5.1−49.2%64.3% | 10—252% | |
| Gross profit | — | — | — | — | 0.1−74.0%— | 0.5−59.3%— | 1.2−38.9%36.3% | 2.0−29.5%29.1% | 2.8—35.7% | −6.1—−152% | |
| Research and development | 18+15.1%— | 16−7.2%— | 17+19.8%— | 14+28.8%— | 11r2.4+128%— | 4.8−63.2%— | 13+31.4%389% | 10+26.8%145% | 7.9+47.6%99.1% | 5.3—134% | |
| Selling and marketing | — | — | — | — | — | 0.7−88.5%— | 6.1−46.2%181% | 11+18.5%164% | 9.6+6.5%120% | 9.0—225% | |
| General and administrative | 9.4+5.6%— | 8.9−10.7%— | 10.0+41.4%— | 7.1+205%— | 2.3r6.3−60.9%— | 5.9−35.6%— | 9.2−13.7%273% | 11−2.2%155% | 11+8.5%137% | 10—252% | |
| Operating expenses | 28+11.7%— | 25−8.5%— | 27+26.9%— | 21+59.4%— | 13r9.1−13.5%— | 15−56.2%— | 35−5.4%1041% | 37+18.2%539% | 31+16.0%395% | 27—678% | |
| Operating income | −28—— | −25—— | −27—— | −21—— | −13r−8.9—— | −15—— | −34—−1005% | −35—−510% | −29—−359% | −33—−830% | |
| Other non-operating income (expense) | 0.9−20.5%— | 1.2−9.3%— | 1.3—— | — | — | — | — | — | — | — | |
| Income before tax | −27—— | −23—— | — | — | — | — | — | — | — | — | |
| Income tax | — | 0.0—— | — | — | — | — | 0—0.0% | 0—0.0% | — | — | |
| Net income attributable to shareholders | −27—— | −23—— | −26—— | −14—— | −13r−8.9—— | −15—— | −34—−994% | −35—−509% | −29—−358% | −33—−829% | |
| Earnings per share, basic | -0.43—— | -0.43—— | -0.50—— | — | -0.27—— | -0.72—— | -2.28—— | -4.23r-0.53—— | -0.53—— | -0.84—— | |
| Earnings per share, diluted | -0.43—— | -0.43—— | -0.50—— | — | -0.27—— | -0.72—— | -2.28—— | -4.23r-0.53—— | -0.53—— | -0.84—— | |
| Shares, weighted average (basic) | 62+13.5%— | 55r0.1+108018%— | 0.1—— | — | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 62+13.5%— | 55r0.1+108018%— | 0.1—— | — | 33+59.5%— | 21+39.9%— | 15+77.3%— | 8.3r66−84.7%— | 54+36.9%— | 40r0.0—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 16−11.6%41.2% | 18−11.1%44.2% | 21−54.2%45.1% | 45+1970%88.2% | 2.2r70+4.7%39.9% | 2.1r3.2−81.6%46.7% | 11+153%68.2% | 4.5−43.0%41.9% | 7.8r0.6−27.9%54.1% | 11r0.5—64.7% | |
| Receivables | — | — | — | — | — | — | 0.5−9.7%2.7% | 0.5−72.5%4.7% | 1.8+568%12.6% | 0.3—1.6% | |
| Inventory | — | — | — | — | — | — | 1.0−68.3%6.2% | 3.3+20.4%30.4% | 2.7−21.0%18.6% | 3.4—20.3% | |
| Other current assets | 1.0−44.9%2.6% | 1.8−23.7%4.4% | 2.4−1.8%5.3% | 2.5+743%4.8% | 0.3r0.9−73.4%5.3% | 1.1+265%24.5% | 0.3−78.6%1.8% | 1.4+75.5%13.1% | 0.8+10.9%5.5% | 0.7—4.3% | |
| Current assets | 18−12.4%45.4% | 20−11.4%49.2% | 23−51.5%50.4% | 48+1825%93.0% | 2.5r71−42.2%45.3% | 4.3−67.4%95.7% | 13+36.3%79.0% | 9.6−26.9%90.1% | 13−13.9%90.8% | 15—90.9% | |
| Loans to customers (net) | — | — | — | — | — | — | — | — | 0−100%0.0% | 0.0—0.0% | |
| Property, plant and equipment | 2.9+70.1%7.3% | 1.7−2.1%4.1% | 1.7+46.3%3.8% | 1.2+0.8%2.3% | 1.2r0.1+574%21.5% | 0.2−84.5%3.9% | 1.1+9.5%6.8% | 1.0−21.1%9.6% | 1.3−12.8%9.0% | 1.5—8.9% | |
| Right-of-use (leased) assets | 17−4.0%43.7% | 18−8.5%43.2% | 20+2418%42.8% | 0.8−51.6%1.5% | 1.6r0.2—29.5% | — | 2.3—14.1% | — | — | — | |
| Total assets | 39−5.2%100% | 42−9.2%100% | 46−10.4%100% | 51+838%100% | 5.5r71+22.3%100% | 4.5−73.1%100% | 17+55.4%100% | 11−26.3%100% | 14−13.8%100% | 17—100% | |
| Accounts payable | 1.0+26.3%2.6% | 0.8+50.7%2.0% | 0.5−54.0%1.2% | 1.2+319%2.3% | 0.3r0.5−42.2%5.2% | 0.5−55.5%10.9% | 1.1−16.2%6.6% | 1.3+73.5%12.2% | 0.8−34.9%5.2% | 1.2—6.9% | |
| Debt due within a year | — | — | — | — | — | 2.2—49.3% | — | — | — | — | |
| Current liabilities | 6.6+10.3%16.8% | 6.0+4.6%14.4% | 5.7−16.1%12.5% | 6.8+227%13.3% | 2.1r2.5−59.4%38.3% | 5.1−26.3%115% | 7.0−8.4%41.9% | 7.6+14.9%71.1% | 6.6+16.8%45.6% | 5.7—33.7% | |
| Lease liabilities (non-current) | 17−5.0%43.3% | 18−7.0%43.2% | 19—42.2% | — | 0.9r0.1—16.5% | — | 2.4—14.2% | — | — | — | |
| Total liabilities | 24−1.2%60.1% | 24−4.3%57.6% | 25+267%54.7% | 6.8+128%13.3% | 3.0r2.5−41.8%54.8% | 5.1−45.0%115% | 9.3+22.7%56.2% | 7.6—71.1% | — | — | |
| Retained earnings | −149—−377% | −122—−293% | −98—−215% | −73—−142% | −59r−329—−1080% | −320—−7167% | −305—−1836% | −269—−2523% | −234—−1617% | −206—−1225% | |
| Shareholders' equity | 16−10.7%39.9% | 18−15.2%42.4% | 21−53.1%45.3% | 44+1697%86.7% | 2.5r68+26.4%45.2% | 2.0r−0.7−73.2%43.7% | 7.3r7.3+136%43.8% | 3.1−60.9%28.9% | 7.9−29.3%54.4% | 11—66.3% | |
| Total equity | — | — | — | — | — | — | — | — | 7.9−29.3%54.4% | 11—66.3% | |
| Total liabilities and equity | 39−5.2%100% | 42−9.2%100% | 46−10.4%100% | 51+838%100% | 5.5r71+22.3%100% | 4.5−73.1%100% | 17+55.4%100% | 11−26.3%100% | 14−13.8%100% | 17—100% | |
| Shares outstanding | 76+29.0%— | 59+16.1%— | 51r0.1+100481%— | 0.1r51−99.9%— | 37r0.0+158438%— | 0.0r23−99.9%— | 16+63.9%— | 9.5r76−83.4%— | 58r58+35.0%— | 43r0.0—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.4+6.0%— | 0.4+12.0%— | 0.4−6.3%— | 0.4+10.4%— | 0.3r0.1+110%— | 0.2−58.7%— | 0.4−8.7%11.7% | 0.4−4.8%6.3% | 0.5+5.8%5.7% | 0.4—10.8% | |
| Share-based compensation | 1.5−7.8%— | 1.6−13.6%— | 1.9+43.8%— | 1.3−22.3%— | 1.7r0.1+296%— | 0.4−85.6%— | 2.9−18.5%86.6% | 3.6−5.2%52.0% | 3.8+12.4%47.5% | 3.4—84.2% | |
| Cash from operating activities | −24—— | −21—— | −24—— | −19—— | −11r−9.2—— | −17—— | −28—−818% | −30—−432% | −24—−301% | −25—−627% | |
| Capital expenditure | −1.2—— | −0.6—— | −0.9—— | −0.3—— | −0.6r−0.0—— | −0.3—— | −0.5—−14.6% | −0.2—−2.4% | −0.3—−3.3% | −0.5—−12.3% | |
| Cash from investing activities | −1.2—— | −0.6—— | −0.9—— | −0.3—— | −0.6r−0.0−941%— | 0.1—— | −0.5—−14.6% | −0.2—−2.4% | −0.3r2.8—−3.3% | −0.5r4.9—−12.3% | |
| Shares issued | — | — | — | — | — | — | — | 26+24.9%376% | 21+6.6%261% | 19—487% | |
| Cash from financing activities | 23+22.1%— | 19+14226%— | 0.1−99.8%— | 63+446%— | 12r76+35.1%— | 8.6−75.4%— | 35+31.5%1035% | 27+25.7%386% | 21+3.5%266% | 20—511% | |
| Exchange-rate effect on cash | — | — | — | — | 0.0−66.7%— | 0.0—— | −0.0−375%−0.3% | 0.0−50.0%0.1% | 0.0r0.0−65.2%0.1% | 0.0r0.0—0.6% | |
| Change in cash | −2.1—— | −2.3—— | −24−155%— | 44+45533%— | 0.1r66—— | −8.2−219%— | 6.9—203% | −3.4—−48.8% | −3.0r0.1—−38.1% | −5.1r0.3—−127% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | 0*—— | 0—— | 0*—— | 0*—— | — | — | — | |
| Research and development | 18+3.9%— | 5.0+11.1%— | 4.5−6.4%— | 4.4+4.1%— | 4.6*+7.6%— | 4.5+7.5%— | 4.8+35.5%— | 4.2+13.2%— | 4.3*−8.6%— | 4.2—— | 3.5—— | 3.7—— | 4.7*—— | |
| General and administrative | 9.5+1.4%— | 2.5+13.8%— | 2.4−10.5%— | 2.4+3.7%— | 2.2*+1.1%— | 2.2+4.7%— | 2.7+24.7%— | 2.3−6.4%— | 2.2*+42.9%— | 2.1—— | 2.2—— | 2.5—— | 1.5*—— | |
| Operating expenses | 28+3.0%— | 7.5+12.0%— | 6.9−7.9%— | 6.8+4.0%— | 6.8*+5.4%— | 6.7+6.6%— | 7.5+31.4%— | 6.6+5.3%— | 6.5*+3.9%— | 6.3—— | 5.7—— | 6.2—— | 6.2*—— | |
| Operating income | −28—— | −7.5—— | −6.9—— | −6.8—— | −6.8*—— | −6.7—— | −7.5—— | −6.6—— | −6.5*—— | −6.3—— | −5.7—— | −6.2—— | −6.2*—— | |
| Other non-operating income (expense) | 1.8+49.7%— | −0.3—— | 0.5—— | −0.2—— | 1.7*−12.0%— | −0.2—— | −0.3—— | −0.3—— | 2.0*—— | −0.3—— | −0.3—— | −0.2—— | — | |
| Net income attributable to shareholders | −27—— | −7.3—— | −6.4—— | −6.8—— | −6.6*—— | −6.5—— | −7.1—— | −6.3—— | −6.1*—— | −6.0—— | −5.4—— | −6.0—— | −6.0*—— | |
| Earnings per share, basic | — | -0.08—— | -0.07—— | -0.08—— | — | -0.11—— | -0.12—— | -0.11—— | — | -0.11—— | -0.10—— | -0.12r0.12—— | — | |
| Earnings per share, diluted | — | -0.08—— | -0.07—— | -0.08—— | — | -0.11—— | -0.12—— | -0.11—— | — | -0.11—— | -0.10—— | -0.12—— | — | |
| Shares, weighted average (basic) | 90+50.9%— | 90+50.9%— | 87+47.0%— | 81+37.2%— | — | 60+8.1%— | 59+7.7%— | 59+13.5%— | — | 55—— | 55—— | 52—— | — | |
| Shares, weighted average (diluted) | 90+50.9%— | 90+50.9%— | 87+47.0%— | 81+37.2%— | — | 60+8.1%— | 59+7.7%— | 59+13.5%— | — | 55—— | 55—— | 52—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 15—41.3% | 15+455%41.3% | 20+193%47.8% | 20+51.8%46.6% | 16−11.6%41.2% | 2.6−86.6%10.5% | 6.8−72.7%23.5% | 13−56.1%36.7% | 18−11.1%44.2% | 20—45.8% | 25—51.7% | 30—55.1% | 21—45.1% | |
| Receivables | — | — | — | 0.0—0.0% | — | — | — | — | — | — | — | — | — | |
| Other current assets | 0.9—2.7% | 0.9+6.1%2.7% | 1.0−27.7%2.5% | 1.1−33.9%2.6% | 1.0−44.9%2.6% | 0.9−49.6%3.5% | 1.4+0.6%4.9% | 1.7−10.1%4.7% | 1.8−23.7%4.4% | 1.8—4.1% | 1.4—2.9% | 1.9—3.4% | 2.4—5.3% | |
| Current assets | 16—44.8% | 16+279%44.8% | 22+148%52.0% | 22+45.1%50.9% | 18−12.4%45.4% | 4.2−80.5%16.7% | 8.7−66.9%30.2% | 15−52.9%41.9% | 20−11.4%49.2% | 21—49.9% | 26—54.6% | 32—58.6% | 23—50.4% | |
| Property, plant and equipment | 2.8—7.8% | 2.8+1.4%7.8% | 2.9+80.7%6.8% | 2.8+71.0%6.5% | 2.9+70.1%7.3% | 2.7+65.8%10.9% | 1.6−7.8%5.5% | 1.6−4.7%4.5% | 1.7−2.1%4.1% | 1.6—3.8% | 1.7—3.5% | 1.7—3.1% | 1.7—3.8% | |
| Right-of-use (leased) assets | 16—44.5% | 16−6.4%44.5% | 16−5.7%38.8% | 17−5.2%39.2% | 17−4.0%43.7% | 17−8.7%67.0% | 17−8.8%59.3% | 18−8.8%49.4% | 18−8.5%43.2% | 18—42.9% | 19—39.0% | 19—35.7% | 20—42.8% | |
| Total assets | 35—100% | 35+41.0%100% | 42+44.1%100% | 42+19.5%100% | 39−5.2%100% | 25−41.6%100% | 29−40.1%100% | 35−34.1%100% | 42−9.2%100% | 43—100% | 48—100% | 54—100% | 46—100% | |
| Accounts payable | 1.2—3.4% | 1.2−15.6%3.4% | 1.2−32.2%2.9% | 1.5+45.9%3.5% | 1.0+26.3%2.6% | 1.4+76.0%5.7% | 1.8+173%6.1% | 1.0+76.1%2.8% | 0.8+50.7%2.0% | 0.8—1.9% | 0.6—1.3% | 0.6—1.1% | 0.5—1.2% | |
| Current liabilities | 6.6—18.6% | 6.6−3.6%18.6% | 6.7−0.8%16.0% | 6.8+9.3%16.0% | 6.6+10.3%16.8% | 6.8+8.9%27.3% | 6.7+16.1%23.2% | 6.2+1.0%17.5% | 6.0+4.6%14.4% | 6.3—14.6% | 5.8—12.0% | 6.1—11.4% | 5.7—12.5% | |
| Lease liabilities (non-current) | 16—43.9% | 16−8.3%43.9% | 16−7.3%38.5% | 16−6.4%38.9% | 17−5.0%43.3% | 17−7.6%67.5% | 17−7.2%59.8% | 18−6.9%49.7% | 18−7.0%43.2% | 18—42.6% | 19—38.6% | 19—35.2% | 19—42.2% | |
| Total liabilities | 22—62.6% | 22−6.9%62.6% | 23−5.5%54.4% | 23−2.4%54.9% | 24−1.2%60.1% | 24−3.4%94.8% | 24−1.7%83.0% | 24−5.0%67.2% | 24−4.3%57.6% | 25—57.3% | 24—50.6% | 25—46.6% | 25—54.7% | |
| Retained earnings | −169—−478% | −169—−478% | −162—−388% | −155—−367% | −149—−377% | −142—−567% | −135—−468% | −128—−362% | −122—−293% | −116—−270% | −110—−228% | −104—−194% | −98—−215% | |
| Shareholders' equity | 13—37.4% | 13+910%37.4% | 19+286%45.6% | 19+64.2%45.1% | 16−10.7%39.9% | 1.3−92.9%5.2% | 4.9−79.4%17.0% | 12−59.5%32.8% | 18−15.2%42.4% | 18—42.7% | 24—49.4% | 29—53.4% | 21—45.3% | |
| Total liabilities and equity | 35—100% | 35+41.0%100% | 42+44.1%100% | 42+19.5%100% | 39−5.2%100% | 25−41.6%100% | 29−40.1%100% | 35−34.1%100% | 42−9.2%100% | 43—100% | 48—100% | 54—100% | 46—100% | |
| Shares outstanding | 76—— | 76+24.3%— | 0.1r89−99.8%— | 85+42.9%— | 76+29.0%— | 62+11.3%— | 59+7.3%— | 59+107659%— | 59+16.1%— | 55—— | 55—— | 0.1—— | 51r0.1—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | 0.1+22.9%— | — | 0.1+27.5%— | 0.1*+29.2%— | 0.1−1.9%— | 0.1−2.9%— | 0.1+3.0%— | 0.1*−9.2%— | 0.1—— | 0.1—— | 0.1—— | 0.1*—— | |
| Share-based compensation | 1.5+3.6%— | 0.4+37.0%— | 0.3−19.9%— | 0.3−10.9%— | 0.5*+16.2%— | 0.3−41.5%— | 0.4+2.1%— | 0.4−0.8%— | 0.4*−12.6%— | 0.5r0.0—— | 0.4r0.0—— | 0.4—— | 0.5*—— | |
| Cash from operating activities | −25—— | −6.4*—— | −6.0*—— | −6.2—— | −6.7*—— | −6.4*—— | −6.1*—— | −5.2—— | −5.8*—— | −5.7*—— | −4.8*—— | −4.5—— | −3.5*—— | |
| Capital expenditure | −0.4—— | 0*—— | −0.1*—— | −0.0—— | −0.3*—— | −0.8*—— | −0.1*—— | −0.0—— | −0.3*—— | −0.0*—— | −0.0*—— | −0.2—— | −0.7*—— | |
| Cash from investing activities | −0.4—— | 0*—— | −0.1*—— | −0.0—— | −0.3*—— | −0.8*—— | −0.1*—— | −0.0—— | −0.3*—— | −0.0*—— | −0.0*—— | −0.2—— | −0.7*—— | |
| Cash from financing activities | 37+396%— | 1.1*−63.1%— | 5.8*—— | 9.7—— | 21*+326%— | 2.9*+590%— | −0.1*−187%— | −0.2−101%— | 4.8*+20891%— | 0.4*—— | 0.1*—— | 14—— | 0.0*—— | |
| Change in cash | 12—— | −5.3*—— | −0.3*—— | 3.5—— | 14*—— | −4.2*—— | −6.2*—— | −5.3−159%— | −1.3*—— | −5.3*—— | −4.7*—— | 9.0—— | −4.2*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Vivani Medical, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Adam Mendelsohn | $878 K | $857 K | $751 K | $145 |
| 2024Adam Mendelsohn | $1.1 M | $915 K | $770 K | $137 |
| 2023Adam Mendelsohn | $1.0 M | $955 K | $694 K | $120 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Vivani Medical, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 6 · Unregistered share sale 5 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2021 | $28 M | Private placement after listing | $10 to $50 million | 7 | equity | SEC |
| Dec 2018 | $3 M | Private placement after listing | $2 to $10 million | 2 | equity | SEC |
| Oct 2018 | $4 M | Private placement after listing | $2 to $10 million | 2 | equity | SEC |
| Aug 2018 | $5 M | Private placement after listing | $2 to $10 million | 2 | equity | SEC |
| May 2018 | $10 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| Sep 2013 | $11 M | No. 5 | $10 to $50 million | 5 | equity | SEC |
| Aug 2013 | $6 M | No. 4 | $2 to $10 million | — | equity | SEC |
| Feb 2012 | $2 M | No. 3 | $2 to $10 million | — | equity | SEC |
| Dec 2011 | $2 M | No. 2 | $2 to $10 million | — | equity | SEC |
| Nov 2009 | $5 M | No. 1 | $2 to $10 million | 19 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Vivani Medical, Inc.#
1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $95 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Chemist IIChemists | 1 | $95 K |
Where: Alameda, CA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Vivani Medical, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018 | · | · | · | · | · | · | · | · | · | 8 | · | · | 8 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 8 people | Restructuring planSEC 8-K | “Specifically, the Company will reduce expenses and personnel by 8 employees related to international commercial operations for the Argus ® II Retinal Prosthesis System (“Argus II”)…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Vivani Medical, Inc. compares in Medical Devices
- Market cap$121 M · higher than 37% of 142
- Revenue growth-51.0% · higher than 3% of 104
- Price / book7.7× · lower than 18% of 99
- FCF yield-21.1% · higher than 27% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Vivani Medical, Inc.🇺🇸 | $121 M | — | — | -51.0% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Vivani Medical, Inc.? Verify and update this profile — free
Show Vivani Medical, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.